Palonosetron
Chemotherapy-induced Gastrointestinal Symptom Cluster
Jiuda ZhaoSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Chemotherapy-induced Gastrointestinal Symptom Cluster cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- Jiuda Zhao | Phase 3 | B |
Olanzapine Jiuda Zhao | Phase 3 | B |
Netupitant Jiuda Zhao | Phase 3 | B |
Zofran Jiuda Zhao | Phase 3 | B |
Tropisetron Jiuda Zhao | Phase 3 | B |
DEXAMETHASONE Jiuda Zhao | Phase 3 | B |
Same molecule, other indications
Palonosetron is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →